Form 4: Werewolf Therapeutics Director Sells Over 100K Shares

Werewolf Therapeutics Director Luke Evnin reported the sale of over 100,000 common shares through pre-arranged 10b5-1 plans.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), reported multiple sales of common stock.
• On November 18, 2025, 33,776 shares were sold at a weighted average price of $0.93, with prices ranging from $0.8902 to $0.9601.
• On November 19, 2025, 42,566 shares were sold at a weighted average price of $0.94, with prices ranging from $0.901 to $0.9806.
• On November 20, 2025, 26,411 shares were sold at a weighted average price of $0.89, with prices ranging from $0.8506 to $0.9556.
• These transactions were executed under a Rule 10b5-1 plan established on September 24, 2025.
• Following these sales, the indirect beneficial ownership of the reporting person stands at 3,413,127 shares.
• The shares are held indirectly through various MPM entities, and Luke Evnin disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to significant insider selling, even if pre-planned. While 10b5-1 plans mitigate the immediate negative interpretation, the sheer volume and relatively low prices of the sales can still be seen as a lack of strong conviction or a need for liquidity, which is generally not a positive signal for investors.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating a planned divestment rather than a reaction to recent negative news.

Negatives

• A director selling a significant number of shares (over 100,000 in total) could be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The sale prices are relatively low, ranging from $0.89 to $0.94, which might reflect a low valuation for the company's stock.

Risks

• The market might interpret the director's sales as a negative signal, potentially leading to downward pressure on the stock price.
• The low share price at which the sales occurred could indicate underlying concerns about the company's valuation or future prospects.

Industry Context

Insider sales, even when pre-scheduled, are often scrutinized in the biotechnology sector, where investor confidence is heavily tied to pipeline progress and management's long-term commitment. While 10b5-1 plans are common for managing personal finances, significant sales can still raise questions about a director's view on future growth, especially for a company like Werewolf Therapeutics which is likely in a development phase.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on stock price due to director selling.
• Employees: No direct impact mentioned, but a declining stock price could affect morale or equity compensation value.

Key Dates

Recommendation

While the insider sales are significant and occurred at relatively low prices, they were executed under a pre-established 10b5-1 plan, which mitigates the immediate negative interpretation of a reactive sale. However, the volume of sales by a director still warrants caution. Investors should hold and monitor future filings and company performance for clearer signals on management's long-term outlook and the company's strategic direction before making further investment decisions.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Biotechnology, SEC Filing